ReviewOncoTargets and therapy2018
Novel EXO-T vaccine using polyclonal CD4
Review in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review.Breast cancer (Dove Medical Press) · 2026Review
- Exosome-based cancer vaccine: a cell-free approach.Molecular biology reports · 2025Review
- Exosomes in esophageal cancer: function and therapeutic prospects.Medical oncology (Northwood, London, England) · 2024Review
- Exosome-like Systems: From Therapies to Vaccination for Cancer Treatment and Prevention-Exploring the State of the Art.Vaccines · 2024Review
- Exploring the dynamic interplay between exosomes and the immune tumor microenvironment: implications for breast cancer progression and therapeutic strategies.Breast cancer research : BCR · 2024Review
- Cancer treatment therapies: traditional to modern approaches to combat cancers.Molecular biology reports · 2023Review
- Sickle Cell Hemoglobin Genotypes Affect Malaria Parasite Growth and Correlate with Exosomal miR-451a and let-7i-5p Levels.International journal of molecular sciences · 2023Article
- Review
- Exosomes: The Role in Tumor Tolerance and the Potential Strategy for Tumor Therapy.Pharmaceutics · 2023Review
- Research progress of exosomes in drug resistance of breast cancer.Frontiers in bioengineering and biotechnology · 2023Review
- MicroRNAs miR-451a and Let-7i-5p Profiles in Circulating Exosomes Vary among Individuals with Different Sickle Hemoglobin Genotypes and Malaria.Journal of clinical medicine · 2022Article
- Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment.Biomolecules · 2022Review
- Identification of CD4Frontiers in immunology · 2022Article
- Exosomes as smart drug delivery vehicles for cancer immunotherapy.Frontiers in immunology · 2022Review
- Small extracellular vesicles in cancer.Bioactive materials · 2021Review
- Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells.Cancers · 2021Review
- Exosomes in Immune Regulation.Non-coding RNA · 2021Review
- Emerging Significance and Therapeutic Potential of Extracellular vesicles.International journal of biological sciences · 2021Review
- The Advancing Roles of Exosomes in Breast Cancer.Frontiers in cell and developmental biology · 2021Review
- Exosomes and breast cancer drug resistance.Cell death & disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the leading cause of death in women globally. The human epidermal growth factor receptor 2 (HER2)-positive breast cancer is often associated with poor prognosis and high mortality. Even though anti-HER2 monoclonal antibodies have improved the clinical outcome, resistance to the antibody therapy becomes a major obstacle in the treatment of HER2-positive breast cancer patients. Alternative approaches are therefore needed. HER2-specific vaccines have been developed to trigger patient's immune system against HER2-positive breast cancer. This article describes the development of novel HER2-specific exosome (EXO)-T vaccine using polyclonal CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.